ClinicalTrials.gg
CompletedNCT00122460Updated Jul 23, 2014Results posted

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

A Phase 3 interventional study of Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) and Platinum (Cisplatin or Carboplatin) + 5-FU in Head and Neck Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 70 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-23.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing fluorouracil in Head and Neck Neoplasms — 4 open to participants now, 5 under way, none of them phase 3. Fluorouracil · Head and Neck Neoplasms.

Enrollment
2nd of 42
442 · median 40
Started
2004
with 2 others
Phase 3
8 of 44
none open now
Registered
15th of 44
by date

Among the 44 studies testing fluorouracil in Head and Neck Neoplasms, this one is the 2nd largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2004, is one of 8 in phase 3, and was the 15th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

4 of the 44 studies testing fluorouracil in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing fluorouracil in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer. Overall survival will be taken as the primary measure of efficacy.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck (SCCHN)
  • Recurrent and/or SCCHN, not suitable for local therapy

Exclusion criteria

Exclusion Criteria:

  • Prior systemic chemotherapy, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 6 months prior to study entry
  • Surgery (excluding prior diagnostic ), or irradiation within 4 weeks before study entry
  • Nasopharyngeal carcinoma
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
442 participants (actual)

Study arms

  • Experimental
    Cetuximab Plus Chemotherapy

    Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)

  • Active comparator
    Chemotherapy alone

    Drug: Platinum (Cisplatin or Carboplatin) + 5-FU

Interventions

  • DrugCetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)

    Drug page: Fluorouracil

    Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks

  • DrugPlatinum (Cisplatin or Carboplatin) + 5-FU

    Drug pages: Platinum Compounds · Fluorouracil

    All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks

06

What researchers measure

Primary outcomes

  1. Overall Survival Time (OS)

    Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

    Time frame: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007

Secondary outcomes

  1. Progression-free Survival Time (PFS)

    Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

    Time frame: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007

  2. Best Overall Response

    The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria).

    Time frame: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007

  3. Disease Control

    The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria).

    Time frame: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007

  4. Time to Treatment Failure

    Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment.

    Time frame: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007

  5. Duration of Response

    Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

    Time frame: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007

  6. Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

    Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

    Time frame: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007

  7. Quality of Life Assessment (EORTC QLQ-C30) Social Functioning

    Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning.

    Time frame: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007

  8. Safety - Number of Patients Experiencing Any Adverse Event

    Please refer to Adverse Events section for further details

    Time frame: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007

07

Results

Posted Sep 30, 2011
Limitations and caveats
Non-specific outcome measures 'Safety' \& 'QOL assessments' were deleted from this entry in error.Replacement outcomes have been created. The 'Safety' outcome refers to adverse events.

Participant flow

First/last subject(informed consent): 14Dec 2004/28 Dec2005. Clinical cut-off: 12 Mar 2007. 80 centers in Europe: Austria (3), Belgium (5), Czech Republic (2), France (12),Germany (8), Hungary (4), Italy (5), Netherlands (4), Poland (5), Portugal (3), Russia (4), Slovakia (2), Spain (9), Sweden (3), Switzerland (3), UK (4), and Ukraine (4).

Participant flow — Overall Study
MilestoneCetuximab Plus ChemotherapyChemotherapy Alone
Started222220
Completed215219
Not completed71
Withdrew: Investigational study phase ongoing71

Outcome measures

PrimaryOverall Survival Time (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

Time frame:
time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Reported as:
Median · months
Overall Survival Time (OS)
monthsCetuximab Plus ChemotherapyChemotherapy Alone
Overall Survival Time (OS)10.1 (8.6 to 11.2)7.4 (6.4 to 8.3)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Stratified Log Rank · p = 0.036 · Hazard ratio (hr): 0.797 · 95% CI 0.644 to 0.986
SecondaryProgression-free Survival Time (PFS)

Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.

Time frame:
time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Reported as:
Median · months
Progression-free Survival Time (PFS)
monthsCetuximab Plus ChemotherapyChemotherapy Alone
Progression-free Survival Time (PFS)5.6 (5.0 to 6.0)3.3 (2.9 to 4.3)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Stratified Log Rank · p = <0.0001 · Hazard ratio (hr): 0.538 · 95% CI 0.431 to 0.672
SecondaryBest Overall Response

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria).

Time frame:
evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Reported as:
Number · percentage of participants
Best Overall Response
percentage of participantsCetuximab Plus ChemotherapyChemotherapy Alone
Best Overall Response35.6 (29.3 to 42.3)19.5 (14.5 to 25.4)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Cochran-Mantel-Haenszel · p = 0.0001 · Odds ratio (or): 2.326 · 95% CI 1.504 to 3.600
SecondaryDisease Control

The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria).

Time frame:
evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Reported as:
Number · percentage of participants
Disease Control
percentage of participantsCetuximab Plus ChemotherapyChemotherapy Alone
Disease Control81.1 (75.3 to 86.0)60.0 (53.2 to 66.5)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.881 · 95% CI 1.870 to 4.441
SecondaryTime to Treatment Failure

Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment.

Time frame:
Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Reported as:
Median · months
Time to Treatment Failure
monthsCetuximab Plus ChemotherapyChemotherapy Alone
Time to Treatment Failure4.8 (4.0 to 5.6)3.0 (2.8 to 3.4)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Stratified Log Rank · p = <0.0001 · Hazard ratio (hr): 0.593 · 95% CI 0.484 to 0.727
SecondaryDuration of Response

Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.

Time frame:
time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Reported as:
Median · months
Duration of Response
monthsCetuximab Plus ChemotherapyChemotherapy Alone
Duration of Response5.6 (4.7 to 6.0)4.7 (3.5 to 5.9)
Statistical analysis
  • Cetuximab Plus Chemotherapy vs Chemotherapy Alone · Stratified Log Rank · p = 0.21 · Hazard ratio (hr): 0.762 · 95% CI 0.497 to 1.168
SecondaryQuality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.

Time frame:
at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
Reported as:
Least squares mean · scores on a scale
Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
scores on a scaleCetuximab Plus ChemotherapyChemotherapy Alone
At baseline50.74 ± 3.51945.15 ± 3.745
At cycle 352.68 ± 3.72445.48 ± 4.153
Month 655.30 ± 4.28242.49 ± 5.959
SecondaryQuality of Life Assessment (EORTC QLQ-C30) Social Functioning

Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning.

Time frame:
at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
Reported as:
Least squares mean · scores on a scale
Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
scores on a scaleCetuximab Plus ChemotherapyChemotherapy Alone
At baseline62.14 ± 4.45962.05 ± 4.730
At cycle 364.64 ± 4.66360.67 ± 5.176
Month 661.27 ± 5.34765.72 ± 7.122
SecondarySafety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for further details

Time frame:
time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
Reported as:
Number · participants
Safety - Number of Patients Experiencing Any Adverse Event
participantsCetuximab Plus ChemotherapyChemotherapy Alone
Safety - Number of Patients Experiencing Any Adverse Event218208

Adverse events

Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab Plus Chemotherapy—110/219 (50.2%)214/219 (97.7%)
Chemotherapy Alone—102/215 (47.4%)198/215 (92.1%)
Most frequent serious events
Showing 10 of 178
Most frequent serious events
EventCetuximab Plus ChemotherapyChemotherapy Alone
DyspnoeaRespiratory, thoracic and mediastinal disorders4/21911/215
AnaemiaBlood and lymphatic system disorders5/21910/215
NeutropeniaBlood and lymphatic system disorders3/21910/215
PneumoniaInfections and infestations10/2194/215
Febrile neutropeniaBlood and lymphatic system disorders8/2199/215
DehydrationMetabolism and nutrition disorders9/2193/215
PyrexiaGeneral disorders2/2197/215
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2197/215
ThrombocytopeniaBlood and lymphatic system disorders4/2196/215
Mucosal inflammationGeneral disorders5/2196/215
Most frequent other events
Showing 10 of 49
Most frequent other events
EventCetuximab Plus ChemotherapyChemotherapy Alone
NauseaGastrointestinal disorders119/219100/215
AnaemiaBlood and lymphatic system disorders92/219111/215
VomitingGastrointestinal disorders84/21979/215
NeutropeniaBlood and lymphatic system disorders83/21977/215
RashSkin and subcutaneous tissue disorders61/2194/215
DiarrhoeaGastrointestinal disorders56/21933/215
AstheniaGeneral disorders56/21947/215
AnorexiaMetabolism and nutrition disorders54/21931/215
Mucosal inflammationGeneral disorders50/21938/215
FatigueGeneral disorders49/21944/215

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
<=18 years000
Between 18 and 65 years183182365
>=65 years393877
Age, Continuous
Age, Continuous(years)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
Mean57.1 ± 8.056.7 ± 8.756.9 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
Female251843
Male197202399
Region of Enrollment
Region of Enrollment(participants)Cetuximab Plus ChemotherapyChemotherapy AloneTotal
Portugal369
Slovakia314
Spain384179
Ukraine181634
Austria41014
Russian Federation9716
United Kingdom459
Switzerland448
Italy141226
France453176
Czech Republic459
Hungary192443
Belgium141630
Poland181836
Germany181432
Netherlands4610
Sweden347
08

Study locations

70 sites
  • Research Site
    Innsbruck, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Bruxelles, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Ceske Budejovice, Czech Republic
  • Research Site
    Prague, Czech Republic
  • Research Site
    Caen, France
  • Research Site
    Dijon, France
  • Research Site
    Lille, France
  • Research Site
    Limoges, France
  • Research Site
    Marseille, France
  • Research Site
    Montpellier, France
  • Research Site
    Nantes-Saint Herblain, France
  • Research Site
    Nice, France
  • Research Site
    Strasbourg, France
  • Research Site
    Toulouse, France
  • Research Site
    Tours, France
  • Research Site
    Vandoeuvre les Nancy, France
  • Research Site
    Berlin, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Frankfurt on the Main, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Munich, Germany
  • Research Site
    Oldenburg, Germany
  • Research Site
    Stuttgart, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Gyor, Hungary
  • Research Site
    Kecskemet, Hungary
  • Research Site
    Nyiregyhaza, Hungary
  • Research Site
    Cuneo, Italy
  • Research Site
    Genoa, Italy
  • Research Site
    Milan, Italy
  • Research Site
    Monserrato, Italy
  • Research Site
    Naples, Italy
  • Research Site
    Rome, Italy
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Nijmegen, Netherlands
  • Research Site
    Gdansk, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Lisbon, Portugal
  • Research Site
    Porto, Portugal
  • Research Site
    Moscow, Russian Federation
  • Research Site
    St. Petersburg, Russian Federation
  • Research Site
    Bratislava, Slovakia
  • Research Site
    Kosice, Slovakia
  • Research Site
    Barcelona, Spain
  • Research Site
    L'Hospitalet de Llobregat, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    San Sebastian, Spain
  • Research Site
    Santander, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Lind, Sweden
  • Research Site
    Umea, Sweden
  • Research Site
    Örebo, Sweden
  • Research Site
    Geneva, Switzerland
  • Research Site
    Thun, Switzerland
  • Research Site
    Zürich, Switzerland
  • Research Site
    Donetsk, Ukraine
  • Research Site
    Kharkiv, Ukraine
  • Research Site
    Kiev, Ukraine
  • Research Site
    Sumy, Ukraine
  • Research Site
    Chelmsford, United Kingdom
  • Research Site
    Edinburgh, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Manchester, United Kingdom
  • Research Site
    Nottingham, United Kingdom
09

References and documents

Publications

  • Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656. PubMed 18784101 ↗
  • Mesia R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010 Oct;21(10):1967-1973. doi: 10.1093/annonc/mdq077. Epub 2010 Mar 24. PubMed 20335368 ↗
  • Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, Bergmann T, Gohler T, Welslau M, Grosse-Thie C, Guntinas-Lichius O, von der Grun J, Balermpas P, Orlowski K, Messinger D, Stenzel KG, Fietkau R. Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer. 2020 Sep 29;20(1):933. doi: 10.1186/s12885-020-07440-w. PubMed 32993574 ↗
  • Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19. PubMed 23265711 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Mar 2007 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2005
First posted
Jul 22, 2005
Start
Dec 2004
Primary completionActual
Mar 2007
CompletionActual
Jan 2011
Results first posted
Sep 30, 2011
Last update
Jul 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00122460
Responsible party
Sponsor
First posted
Jul 22, 2005
Start date
Dec 2004
Primary completion
Mar 2007
Completion
Jan 2011
Results posted
Sep 30, 2011
Last update
Jul 23, 2014

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Platinum Compounds

Start the discussion